New smart drug target site-specific inflammation and reduce side effects
Ben-Gurion University researchers have developed a dynamic "smart" drug that targets inflammation in a site-specific manner and reduce side-effects. Study is reported in reported in the current issue of Journal of Immunology.
[adsense:336x280:8701650588]
This novel anti-inflammatory molecule when injected it acts as a non-active drug and a localized site with excessive inflammation will activate it. The researchers demonstrated their findings in a mouse model of local inflammation.
"This development is important because inhibition of inflammation in a non-specific manner reduces the natural ability to fight infections and is a common side effect of anti-inflammatory biologic therapeutics," said one of the researchers Peleg Rider from Ben-Gurion University of the Negev (BGU), Israel.
"The beauty of this invention lies in the use of a known natural biological code. We mimicked a natural process that occurs during inflammation," Rider said. "Upon resolution of inflammation, the activation of the protein is also reduced and side effects are avoided," he added.
Subscribe to PharmaTutor News Alerts by Email >>